Alemtuzumab (Campath-1H)

DRUG3 trials

Sponsors

M.D. Anderson Cancer Center, Ontario Clinical Oncology Group (OCOG), Chronic Lymphocytic Leukemia Research Consortium

Conditions

B-Cell Chronic Lymphocytic LeukemiaHodgkin's DiseaseLymphomaPeripheral T-cell Lymphomas

Phase 1

Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas

CompletedNCT00453427

Ontario Clinical Oncology Group (OCOG)Peripheral T-cell Lymphomas

Start: 2006-09-30End: 2015-05-31Updated: 2015-06-03

Phase 2

Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease

WithdrawnNCT00129753

M.D. Anderson Cancer CenterHodgkin's Disease, Lymphoma

Start: 2005-06-22End: 2006-09-05Updated: 2018-11-08

Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy

Chronic Lymphocytic Leukemia Research ConsortiumB-Cell Chronic Lymphocytic Leukemia

Start: 2003-12-31End: 2010-08-31Updated: 2008-12-03